Receptor (TNFRSF)-Interacting serine-threonine Kinase 1 (RIPK1) (C-Term) Peptide

Details for Product No. ABIN1382186, Supplier: Log in to see
Protein Name
  • C9orf12
  • RGD1311271
  • rIpk1
  • RIP
  • RIP1
  • D330015H01Rik
  • Rinp
  • Rip1
  • 2400006N03Rik
  • RP23-83I13.5
  • Rip
  • receptor (TNFRSF)-interacting serine-threonine kinase 1
  • inositol 1,3,4,5,6-pentakisphosphate 2-kinase
  • RPA interacting protein
  • LOC100230522
  • Ippk
  • RIPK1
  • Ripk1
  • Rpain
Protein Region
Blocking Peptide (BP)
Log in to see
Supplier Product No.
Log in to see
Characteristics 14 amino acids near the carboxy terminus of human RIP1.
Research Area Immunology, Innate Immunity, Apoptosis/Necrosis
Application Notes RIP1 peptide is used for blocking the activity of RIP1 antibody. It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37 °C.
Restrictions For Research Use only
Format Liquid
Concentration 200 μg/mL
Buffer PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1 % bovine serum albumin and 0.02 % sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Expiry Date 12 months
Background publications Stanger, Leder, Lee, Kim, Seed: "RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death." in: Cell, Vol. 81, Issue 4, pp. 513-23, 1995 (PubMed).